Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 901 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus Infection Clear all
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

NCT00489385
View directory record Official record
Conditions
HIV Infections, HCV
Interventions
Albinterferon, Ribavirin, Albuferon
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

NCT00726882
View directory record Official record
Conditions
HCV Infection
Interventions
Blood sample collection only, ABT-333
Procedure · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 1Phase 2 Interventional

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

NCT01825980
View directory record Official record
Conditions
Hepatitis C
Interventions
BZF961, Ritonavir, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
San Diego, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Herpes Simplex Type 1 Suppression in Hepatitis C

NCT01580995
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

NCT02201953
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3

NCT04268173
View directory record Official record
Conditions
Drug Use Disorders, Hepatitis C, Harm Reduction, Opioid-use Disorder
Interventions
Community-Based, Client-Centered Prevention Home
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Appleton, Wisconsin • Eau Claire, Wisconsin • Green Bay, Wisconsin + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

NCT01331850
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO5024048, danoprevir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 1:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Project I Test: Implementing HIV Testing in Opioid Treatment Programs

NCT03135886
View directory record Official record
Conditions
HIV/AIDS, Hepatitis C, Substance Use Disorders, Opioid-use Disorder
Interventions
Information Control, HIV and HCV Testing Practice Coaching Intervention, HIV Testing Practice Coaching Intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01181427
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-267, Placebo, Blood Sample Collection, Cytochrome P450 inhibitor
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Waukegan, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

NCT01058512
View directory record Official record
Conditions
Hepatitis C
Interventions
NOV-205
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

NCT00947440
View directory record Official record
Conditions
Hepatitis C
Interventions
ABT-072
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

NCT00758043
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir, ribavirin, peginterferon alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Silymarin for Chronic Liver Diseases

NCT00389376
View directory record Official record
Conditions
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Silymarin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Oct 14, 2026, 1:30 PM EDT
Completed No phase listed Observational

Virology Follow up Study in Subjects Previously Treated With Telaprevir

NCT00916474
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

NCT03214679
View directory record Official record
Conditions
Hepatitis C, People Who Inject Drugs, PWID, HCV Coinfection
Interventions
Accessible Care, Usual Care
Other
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Open-Label Hepatic Impairment Study

NCT01497327
View directory record Official record
Conditions
Hepatitis C
Interventions
PSI-352938, PSI-7977
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 14, 2026, 1:30 PM EDT
Active, not recruiting Phase 1 Interventional

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

NCT02772003
View directory record Official record
Conditions
Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma
Interventions
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

NCT03235154
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 14, 2026, 1:30 PM EDT
Terminated No phase listed Observational

Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C

NCT06564051
View directory record Official record
Conditions
Chronic Viral Hepatitis C, Monoclonal B-Cell Lymphocytosis
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 4 Interventional

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

NCT00207402
View directory record Official record
Conditions
Hepatitis C
Interventions
rosiglitazone
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 14, 2026, 1:30 PM EDT
Not listed No phase listed Observational

Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

NCT02485262
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir and simeprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 14, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 14, 2026, 1:30 PM EDT